Repeated injections of ocriplasmin in the Göttingen mini-pig

Jean HM Feyen (TG), Kelly Tonnison (CRL), Bart Jonckx (TG), TG: ThromboGenics NV, Gaston Geensdries 1, 3001 Leuven, Belgium; CRL: Charles River Laboratories, 22022 Transcanadian, Senneville QC H9X 3R3, Canada

Financial disclaimer: JF; BJ: employees of ThromboGenics NV; KT: employee of Charles River Laboratories

#4043

The purpose of this study was to determine the safety of up to six consecutive intravitreal (IVT) injections of ocriplasmin in the mini-pig.

**Methods**

- Two (2), 3 and 6 ocriplasmin injections 4 weeks apart, were administered by IVT to Göttingen mini-pigs. Each group consisted of 3 males and 3 females. The experimental eye received ocriplasmin at a dose of 63 µg/eye.
- The vehicle was given to the contralateral eye which acted as a control. Fifty (50) microliters were injected mid vitreous with a 29G ½” needle.
- Animals were subjected to ophthalmic toxicology screening consisting of funduscopic and biomicroscopic slit lamp examination (mydriatic and non-mydriatic) and tonometry. In addition a monthly full-field ERG was performed. Enucleated eyes were processed for detailed histopathological analysis at the Charles River Laboratories in Montreal.

**Table 1: Experimental Design**

<table>
<thead>
<tr>
<th>Group No.</th>
<th>Test Material</th>
<th>Dose Level (µg/eye/dose)</th>
<th>Dose Volume (µL)</th>
<th>No. of Animals</th>
<th>Dosing Days</th>
<th>Scheduled Euthanasia Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ocriplasmin</td>
<td>63</td>
<td>50</td>
<td>3</td>
<td>1-28, 56</td>
<td>86</td>
</tr>
<tr>
<td>2</td>
<td>Ocriplasmin</td>
<td>63</td>
<td>50</td>
<td>3</td>
<td>30-57, 117</td>
<td>147</td>
</tr>
<tr>
<td>3</td>
<td>Ocriplasmin</td>
<td>63</td>
<td>50</td>
<td>3</td>
<td>30-57, 117</td>
<td>277</td>
</tr>
</tbody>
</table>

**Table 2: Noteworthy ophthalmic findings**

<table>
<thead>
<tr>
<th>Finding</th>
<th>Timepoint</th>
<th>Incidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lens subluxation</td>
<td>5th injection</td>
<td>4/6</td>
<td>Recorded as a very slight apheric crescent in the superotemporal aspect of the lens</td>
</tr>
<tr>
<td>Anterior uveitis</td>
<td>6th injection</td>
<td>1/6</td>
<td>Moderate and transient anterior uveitis consisting of anterior chamber cells and flare, keratic precipitates, corneal vascularization, iris hyperemia and incomplete pupil dilation. These changes had resolved prior to necropsy.</td>
</tr>
</tbody>
</table>

**Conclusions**

Findings considered not related to ocriplasmin administration:

- One animal had grayish vitreal opacities beginning prior to the last dose, which were suspected to be related to previous minor vitreal hemorrhage that occurred at time of dosing and therefore, were secondary to the experimental procedures.
- Minor and transient conjunctival hyperemia in both eyes and a bulbar conjunctival mass in No. 3502 were secondary to the ERG procedures (ocular manipulation and suture placement).

**Results**

- An apparent reduction in b-wave amplitude was observed on Day 53, following the second dose. No changes were observed in the a-wave. Although the reason for this reduction is unknown, it was considered to be unrelated to test item administration for the following reasons:
  - Responses remained normal in several other ocriplasmin-treated eyes at this occasion.
  - No effect on b-wave amplitude was observed at subsequent occasions following additional doses and.
  - There were no correlating ophthalmology or microscopic findings.
- One (1) animal developed a moderate and transient anterior uveitis in the treated eye following the last (6th) ocriplasmin injection consisting of anterior chamber cells and flare, keratic precipitates, corneal vascularization, iris hyperemia and incomplete pupil dilation; these changes had resolved prior to necropsy.
- In the group receiving up to 6 injections, lens subluxation, recorded as a very small apheric crescent in the superotemporal lens quadrant, was noted in four out of six eyes following the 5th injection. Damage to the lens zonules was noted supero temporally. After 6 administrations, microscopic findings of minimal mononuclear cell infiltration (vitreous, 4/6 eyes; injection site, 2/6 eyes; iridociliary body, 2/6 eyes) were noted. No signs of inflammation or lens subluxation were observed in the control eyes.

**For additional information, please contact bart.jonckx@thrombogenics.com**

www.thrombogenics.com